SPDR SSGA US Equity Premium Income ETF SPIN 深 滬
等待開盤 11-26 09:30:00 美东时间
32.1684
+0.303
+0.95%
華盛通- 最 高32.1684
- 今 開31.70
- 成交量 5711股
- 最 低 31.70
- 昨 收 31.8653
- 總市值 6369.34万
- 52周最高 32.535
- 市盈率 靜 --
- 換手率 0.29%
- 52周最低 23.7388
- 委 比 0.00%
- 總股本 198.00万
- 歷史最高 32.4539
- 量 比 0.08
- 振 幅 1.47%
- 歷史最低 23.7388
- 每 手 1
- 風險率 1.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多It's JPMorgan Vs. State Street In ETF Industry's First Brawl: Who Won?
A look at how JEPI and SPIN stack up as fresh data highlights the differences between the blockbuster and its newer rival.
今天 04:43
Telomir Pharmaceuticals Announces Telomir-1 Shown To Kill Aggressive Human Leukemia Cells
Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells The findings expand Telomir-1's oncology profile into cancers of the blood, adding to previously reported activity in triple-negative
11-21 05:05
HONEYWELL COMPLETES SPIN-OFF OF SOLSTICE ADVANCED MATERIALS
Solstice to begin trading today on Nasdaq under the ticker symbol "SOLS" Spin-off advances Honeywell's plan to create three independent, focused market leaders Separation of Automation and A...
10-30 19:00
HONEYWELL BOARD OF DIRECTORS APPROVES SPIN-OFF OF SOLSTICE ADVANCED MATERIALS
Spin-off distribution remains on track for October 30, 2025 Solstice will be a pure-play specialty materials company with leading market positions in refrigerants, semiconductor materials, d...
10-16 19:00
Telomir-1 Demonstrates Anti-Tumor Activity In Pancreatic Cancer Models, Reinforcing Epigenetic And Metabolic Impact Across Multiple Cancers
Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighting Telomir-1's consistent impact on cancer cell survival pathways.MIAMI, FLORIDA / ACCESS
10-14 20:10
Telomir Pharmaceuticals Reports Telomir-1 Resets DNA Methylation Of Tumor Suppressor Genes Implicated In Two Of The Most Persistent Challenges In Oncology, Metastasis And Treatment Resistance
Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in
10-07 04:20
Biogen Faces FDA Setback On High-Dose Nusinersen Filing For Spinal Muscular Atrophy
On Tuesday, the U.S.
09-25 23:27
Ionis and Biogen Report Early Success With Once-Yearly SMA Treatment Showing Strong Safety and Efficacy Signals
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that its partner, Biogen, shared positive topline results from the Phase 1 study of salanersen (ION306/BIIB115), an investigational antisense oligonucleotide
06-25 19:34
新股消息 | 兆易创新(603986.SH)递表港交所 在NOR Flash领域全球领先
据港交所6月19日披露，兆易創新科技集團股份有限公司(603986.SH)(简称：兆易创新)向港交所主板递交上市申请，中金公司、华泰国际为其联席保荐人。
06-20 06:59
